Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q15208

UPID:
STK38_HUMAN

ALTERNATIVE NAMES:
NDR1 protein kinase; Nuclear Dbf2-related kinase 1

ALTERNATIVE UPACC:
Q15208; Q503A1

BACKGROUND:
The Serine/threonine-protein kinase 38, known alternatively as NDR1 protein kinase and Nuclear Dbf2-related kinase 1, is a key regulator in the MAP3K1/2 signaling pathway. By converting MAP3K2 to its non-phosphorylated state and inhibiting its autophosphorylation, it serves an essential role in controlling signal transduction processes within the cell.

THERAPEUTIC SIGNIFICANCE:
The exploration of Serine/threonine-protein kinase 38's function offers promising avenues for therapeutic development. Given its critical role in modulating MAP3K1/2 signaling, targeting this kinase could lead to innovative treatments for diseases where this pathway is dysregulated. The potential for developing targeted therapies makes it a significant focus of drug discovery efforts.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.